Preview Mode Links will not work in preview mode

Clinical Literature Summaries presented by InpharmD™ (S4))


Dec 10, 2020

A randomzied, double-blind, placebo-controlled, multicenter, phase 2, pilot trial conducted to determine whether inhaled SNG001 (recombinant interferon beta-1a) has the potential to reduce the severity of lower respiratory tract illness and accelerate recovery in patients diagnosed with COVID-19.